Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market patterns of diabetic retinopathy (DR) are outstandingly influenced by the rising pervasiveness of diabetes on a worldwide scale. An expansion in the commonness of diabetic retinopathy, a serious visual entanglement of diabetes, corresponds with the expanded consciousness of diabetes as a general medical problem.
Mechanical Headways: The steady advancement of symptomatic and restorative innovations is one of the essential variables driving the diabetic retinopathy market. Headways in innovation, including imaging frameworks fueled by man-made brainpower (man-made intelligence), telemedicine arrangements, and painless screening strategies, are turning out to be progressively unmistakable in the field of diabetic retinopathy the executives and early discovery.
An Undeniably Maturing Populace: The diabetic retinopathy market is growing fundamentally to a great extent because of the maturing populace. The probability of creating diabetes and its related intricacies, like diabetic retinopathy, raises with propelling age. The significant patient pool created by this segment change has expanded the interest in powerful medicines and the board systems.
Programs for Screening and Mindfulness: Expanding diabetic patient consciousness of diabetic retinopathy and the meaning of routine eye assessments is driving business sector extension. Evaluating programs for early recognition of diabetic retinopathy are overall effectively advanced by legislatures, non-benefit associations, and medical services suppliers. Such drives intend to work on understanding results and relieve medical care uses.
Biopharmaceutical Innovative work: The growing pipeline of prescriptions intended to treat diabetic retinopathy exhibits the drug business' commitment to innovative work. A significant pattern in the treatment of diabetic retinopathy is the quest for additional designated and useful treatments; various biopharmaceutical organizations are dispensing assets towards clinical preliminaries and medication improvement with an end goal to fill the holes around here.
The consolidation of teleophthalmology administrations has turned into a huge improvement on the lookout for diabetic retinopathy. Telemedicine works with discussions, judgments, and remote observing, consequently expanding the accessibility of specific consideration in underserved regions. It is guessed that this pattern will keep on gaining force, particularly considering the developing acknowledgment of virtual medical care arrangements.
The pervasiveness of vital joint efforts and associations is expanding among medical services associations, research organizations, and drug organizations. The target of these associations is to consolidate information, assets, and innovation to speed up the making of novel therapeutics and diagnostics for diabetic retinopathy.
The diabetic retinopathy market is being affected by government drives and approaches that are focused on the administration and counteraction of diabetes. The climate is altogether affected by subsidizing support, repayment strategies, and administrative structures; these components rouse partners to connect effectively in endeavors to handle the hardships introduced by diabetic retinopathy.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Market Opportunities | lack of awareness about treatment |
Diabetic Retinopathy Market Highlights:
Diabetic Retinopathy Market Overview
The diabetic retinopathy market is projected to expand USD 6.7 billion at a CAGR 6.4% during the forecast period 2023-2032. Diabetes mellitus (DM) is a long-term condition defined by high blood glucose levels caused by insufficient insulin synthesis or insulin resistance. Diabetic retinopathy is a consequence of diabetes that results in retinal damage. This illness causes vision loss and eventually blindness. Diabetic retinopathy has a significant economic impact on healthcare systems, in addition to the direct impact on patients' quality of life. Diabetic retinopathy is the most common cause of legal blindness in those aged 20 to 74.
An increase in diabetes prevalence, a rise in the senior population, an increase in the incidence of diabetes-related blindness, and a greater focus on early identification to manage diseases are driving the market. As new technology and minimally painful laser procedures with quick recovery become accessible, patients' willingness to undergo surgical treatments is expected to rise. Furthermore, new ophthalmic gadgets and systems have simplified diagnostic and surgical procedures, which has aided the industry's expansion.
Diabetic Retinopathy Market Segmentation
The Global Diabetic Retinopathy Market has been segmented based on type, treatment, end-user, and region.
The market, based on type, has been segmented into non-proliferative and proliferative.
The market, based on treatment, has been segmented into anti-VEGF drugs, laser photocoagulation, vitreoretinal surgery, and steroid injection.
The market, based on end-user, has been segmented into hospitals, ambulatory surgical centers, and others.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The diabetic retinopathy market in the Americas has further segmented into North America and Latin America, with the North American market divided into the US and Canada. The European diabetic retinopathy industry has been sub-divided into Western Europe and Eastern Europe. Western Europe has further the as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The diabetic retinopathy Industry in the Middle East & Africa has been divided into the Middle East and Africa.
The key players in the Global Diabetic Retinopathy Market are
F.Hoffmann-La Roche AG,
Regeneron Pharmaceuticals, Inc.,
Alimera Sciences,
Ampio Pharmaceuticals Inc.,
Aurolab, Allergan PLC,
others.
Regional Market Summary
Diabetic Retinopathy Global Market Share by Region, 2018 (%)
Source: World Health Organization (WHO)
The market in the Americas is expected to dominate the diabetic retinopathy market due to the presence of major established players in the region and increasing R&D expenses.
Europe is expected to hold the second-largest position in the diabetic retinopathy global market. This can be attributed to the presence of a well-established healthcare system and an increased prevalence of diabetes.
Asia-Pacific is expected to be the fastest-growing regional market owing to the increasing pool of population and increasing awareness about the products.
The diabetic retinopathy market in the Middle East & Africa is projected to account for the least share of the global market due to low disposable income in the region.
Recent Development
A team of University of Pennsylvania researchers discovered that taking a medicine used to lower cholesterol levels in the bloodstream can minimize the likelihood of developing proliferative diabetic retinopathy (PDR) from non-proliferative diabetic retinopathy (NPDR). The researchers talked about their cohort study, which included 5,835 patients who took fenofibrate and 144,417 who didn't, and what they learned regarding the drug's efficacy in reducing DME, PDR, and vision-threatening diabetic retinopathy (VTDR).
iHealthScreen Inc. has announced that the iPredictTM Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age-Related Macular Degeneration (AMD), and Glaucoma Suspect was approved by the Australian Health. The AI Eye Screening System does completely automated diabetic retinopathy, age-related macular degeneration, and glaucoma suspect screening. Primary care and specialized practices can use the iPredictTM System to effectively and quickly screen diabetic patients for DR, persons over 50 for AMD, and people with a suspected risk of glaucoma.
Diabetic Retinopathy Market, by Type
- Non-Proliferative
- Proliferative
Diabetic Retinopathy Market, by Treatment
- Anti- VEGF Drugs
- Laser Photocoagulation
- Vitreoretinal Surgery
- Steroid Injection
Diabetic Retinopathy Market, by End User
- Hospitals
- Ambulatory Surgical Centers
- Others
Diabetic Retinopathy Market, by Region
Americas
- North America
- US
- Canada
- Latin America
Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Middle East & Africa
-
Middle East
-
Africa
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
